» Articles » PMID: 30594967

Adipose Stem Cell Crosstalk with Chemo-residual Breast Cancer Cells: Implications for Tumor Recurrence

Overview
Specialty Oncology
Date 2018 Dec 31
PMID 30594967
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Most triple-negative breast cancer (TNBC) patients exhibit an incomplete response to neoadjuvant chemotherapy, resulting in chemo-residual tumor cells that drive tumor recurrence and patient mortality. Accordingly, strategies for eliminating chemo-residual tumor cells are urgently needed. Although stromal cells contribute to tumor cell invasion, to date, their ability to influence chemo-residual tumor cell behavior has not been examined. Our study is the first to investigate cross-talk between adipose-derived stem cells (ASCs) and chemo-residual TNBC cells. We examine if ASCs promote chemo-residual tumor cell proliferation, having implications for tumor recurrence.

Methods: ASC migration toward chemo-residual TNBC cells was tested in a transwell migration assay. Importance of the SDF-1α/CXCR4 axis was determined using neutralizing antibodies and a small molecule inhibitor. The ability of ASCs to drive tumor cell proliferation was analyzed by culturing tumor cells ± ASC conditioned media (CM) and determining cell counts. Downstream signaling pathways activated in chemo-residual tumor cells following their exposure to ASC CM were studied by immunoblotting. Importance of FGF2 in promoting proliferation was assessed using an FGF2-neutralizing antibody.

Results: ASCs migrated toward chemo-residual TNBC cells in a CXCR4/SDF-1α-dependent manner. Moreover, ASC CM increased chemo-residual tumor cell proliferation and activity of extracellular signal-regulated kinase (ERK). An FGF2-neutralizing antibody inhibited ASC-induced chemo-residual tumor cell proliferation.

Conclusions: ASCs migrate toward chemo-residual TNBC cells via SDF-1α/CXCR4 signaling, and drive chemo-residual tumor cell proliferation in a paracrine manner by secreting FGF2 and activating ERK. This paracrine signaling can potentially be targeted to prevent tumor recurrence.

Citing Articles

Peritoneal adipose stem cell-derived extracellular vesicles mediate the regulation of ovarian cancer cell proliferation and migration through EGFR-NF-κB signaling.

Wang L, Luo N, Zhu J, Sulaiman Z, Yang W, Hu K Genes Dis. 2025; 12(2):101283.

PMID: 39759123 PMC: 11699730. DOI: 10.1016/j.gendis.2024.101283.


Exploring the multifaceted role of obesity in breast cancer progression.

Kakkat S, Suman P, Turbat-Herrera E, Singh S, Chakroborty D, Sarkar C Front Cell Dev Biol. 2024; 12():1408844.

PMID: 39040042 PMC: 11260727. DOI: 10.3389/fcell.2024.1408844.


Understanding the mechanisms underlying obesity in remodeling the breast tumor immune microenvironment: from the perspective of inflammation.

Zhang H, Wang M, Xu Y Cancer Biol Med. 2023; 20(4).

PMID: 36880535 PMC: 10157808. DOI: 10.20892/j.issn.2095-3941.2022.0547.


Individual Variabilities in Adipose Stem Cell Proliferation, Gene Expression and Responses to Lipopolysaccharide Stimulation.

Yasmeen R, Pham Q, Fukagawa N, Wang T Int J Mol Sci. 2022; 23(20).

PMID: 36293398 PMC: 9604277. DOI: 10.3390/ijms232012534.


ADSCs stimulated by resistin promote breast cancer cell malignancy via CXCL5 in a breast cancer coculture model.

Wang Y, Hung A, Wu Y, Lo S, Chen H, Chen Y Sci Rep. 2022; 12(1):15437.

PMID: 36104403 PMC: 9475041. DOI: 10.1038/s41598-022-19290-6.


References
1.
Krejci P, Faitova J, Laurell H, Hampl A, Dvorak P . FGF-2 expression and its action in human leukemia and lymphoma cell lines. Leukemia. 2003; 17(4):818-20. DOI: 10.1038/sj.leu.2402861. View

2.
Zheng B, Fiumara P, Li Y, Georgakis G, Snell V, Younes M . MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood. 2003; 102(3):1019-27. DOI: 10.1182/blood-2002-11-3507. View

3.
Rouzier R, Perou C, Fraser Symmans W, Ibrahim N, Cristofanilli M, Anderson K . Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005; 11(16):5678-85. DOI: 10.1158/1078-0432.CCR-04-2421. View

4.
Carey L, Dees E, Sawyer L, Gatti L, Moore D, Collichio F . The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13(8):2329-34. DOI: 10.1158/1078-0432.CCR-06-1109. View

5.
Liedtke C, Mazouni C, Hess K, Andre F, Tordai A, Mejia J . Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81. DOI: 10.1200/JCO.2007.14.4147. View